DVA
Status-Quo-PlayerDaVita
$151.56
+0.95%
as of 13 Apr
Power Core
DaVita's moat is the geographic density of a 2,700-clinic network in a market where patient demand is biologically non-discretionary and new entrants face a decade-long build cycle against uncertain reimbursement economics.
Direction of Movement
Defended Stasis Between Regulatory Pressure and Buyback Discipline
ROC 200
+5.6%
DVA
DaVita
$151.56
+0.95%
as of 13 Apr
DCF Fair Value: $321.71
Market data unavailable
Company Profile
DaVita Inc. is a leading healthcare provider specializing in kidney care services for patients with chronic kidney failure. The company operates primarily through its US Dialysis and Related Lab Services segment, delivering dialysis treatments at outpatient facilities across the United States, complemented by laboratory services essential for patient monitoring and care management. It also maintains Other-Ancillary Services and Strategic Initiatives, which encompass integrated kidney care solutions and innovative approaches to enhance patient outcomes. DaVita Inc. focuses on transforming care delivery through clinical quality leadership and advancements in kidney health management, serving as a key player in the renal care sector by providing comprehensive services that support patients' quality of life. Headquartered in Denver, Colorado, and founded in 1994, DaVita Inc. stands as the largest provider of kidney care services in the U.S., emphasizing operational excellence in dialysis and ancillary support.